Circulating tumor DNA (ctDNA) is made up of DNA pieces released by cancer cells into the blood. The session "Circulating Tumor DNA" emphasizes its use as a minimally invasive biomarker in cancer detection, monitoring, and targeted treatment.".
ctDNA analysis allows clinicians to identify genetic mutations, monitor tumor evolution, and monitor response to treatment in real time. In contrast to conventional tissue biopsies, liquid biopsies with ctDNA provide a safe, repeatable, and dynamic way to monitor disease status, even in inaccessible tumors. This technology has proved especially useful in early detection, prognosis, and the detection of minimal residual disease.
The session also discusses applications in precision oncology, such as the direction of targeted therapies, the detection of onset resistance mutations, and tailoring of treatment strategies to the individual patient. Next-generation sequencing, digital PCR, and bioinformatics are improving the sensitivity and specificity of the detection of ctDNA.
Participants will learn about the clinical uses, research progress, and future directions of ctDNA in cancer treatment. The emphasis of this session is how circulating tumor DNA revolutionizes oncology as a non-invasive, accurate, and dynamic discriminator for diagnosis, monitoring, and targeted treatment strategies.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
